0001193125-24-016705.txt : 20240126 0001193125-24-016705.hdr.sgml : 20240126 20240126160601 ACCESSION NUMBER: 0001193125-24-016705 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240125 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240126 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERU INC. CENTRAL INDEX KEY: 0000863894 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 391144397 STATE OF INCORPORATION: WI FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-13602 FILM NUMBER: 24567760 BUSINESS ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 BUSINESS PHONE: 3125959123 MAIL ADDRESS: STREET 1: 2916 N. MIAMI AVENUE STREET 2: SUITE 1000 CITY: MIAMI STATE: FL ZIP: 33127 FORMER COMPANY: FORMER CONFORMED NAME: FEMALE HEALTH CO DATE OF NAME CHANGE: 19960205 FORMER COMPANY: FORMER CONFORMED NAME: WISCONSIN PHARMACAL COMPANY INC DATE OF NAME CHANGE: 19920703 8-K 1 d746856d8k.htm 8-K 8-K
NASDAQ false 0000863894 0000863894 2024-01-25 2024-01-25

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 25, 2024

 

 

VERU INC.

(Exact name of registrant as specified in its charter)

 

 

 

Wisconsin   1-13602   39-1144397
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

2916 N. Miami Avenue, Suite 1000, Miami, Florida 33127

Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (305) 509-6897

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange
on which registered

Common Stock, $0.01 par value per share   VERU   NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On January 25, 2024, Veru Inc. (the “Company”) received notification from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the requirement to maintain a minimum closing bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company’s common stock (the “Common Stock”) was below $1.00 per share for 30 consecutive business days. The notification does not impact the listing of the Company’s Common Stock on the Nasdaq Capital Market at this time.

In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days from the date of notification, or until July 23, 2024, to regain compliance with the minimum bid price requirement. During this period, the Company’s Common Stock will continue to trade on the Nasdaq Capital Market. If at any time before July 23, 2024, the bid price of the Company’s Common Stock closes at or above $1.00 per share for a minimum of 10 consecutive trading days (which period may be extended to greater than 10 consecutive trading days at the sole discretion of Nasdaq), Nasdaq will provide written notification that the Company has achieved compliance with this minimum bid price requirement.

In the event the Company does not regain compliance by July 23, 2024, the Company may be eligible for an additional 180 calendar day compliance period to demonstrate compliance with the bid price requirement. To qualify for the additional 180-day period, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not qualify for the second compliance period or fails to regain compliance during the second 180-day period, then Nasdaq will notify the Company of its determination to delist the Company.

 

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: January 26, 2024   VERU INC.
    By:  

/s/ Michele Greco

      Michele Greco
     

Chief Financial Officer and

Chief Administrative Officer

 

3

EX-101.SCH 2 veru-20240125.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 veru-20240125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 veru-20240125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 25, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0000863894
Document Type 8-K
Document Period End Date Jan. 25, 2024
Entity Registrant Name VERU INC.
Entity Incorporation State Country Code WI
Entity File Number 1-13602
Entity Tax Identification Number 39-1144397
Entity Address, Address Line One 2916 N. Miami Avenue
Entity Address, Address Line Two Suite 1000
Entity Address, City or Town Miami
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33127
City Area Code (305)
Local Phone Number 509-6897
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.01 par value per share
Trading Symbol VERU
Entity Emerging Growth Company false
XML 6 d746856d8k_htm.xml IDEA: XBRL DOCUMENT 0000863894 2024-01-25 2024-01-25 NASDAQ false 0000863894 8-K 2024-01-25 VERU INC. WI 1-13602 39-1144397 2916 N. Miami Avenue Suite 1000 Miami FL 33127 (305) 509-6897 false false false false Common Stock, $0.01 par value per share VERU false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d746856d8k.htm veru-20240125.xsd veru-20240125_lab.xml veru-20240125_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d746856d8k.htm": { "nsprefix": "veru", "nsuri": "http://verupharma.com/20240125", "dts": { "inline": { "local": [ "d746856d8k.htm" ] }, "schema": { "local": [ "veru-20240125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "veru-20240125_lab.xml" ] }, "presentationLink": { "local": [ "veru-20240125_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-01-25_to_2024-01-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d746856d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-01-25_to_2024-01-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d746856d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://verupharma.com//20240125/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-24-016705-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-016705-xbrl.zip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